Effect of Montelukast on Treatment of Coronavirus Pneumonia (COVID-19): A Systematic Review
Hanieh Salehi-Pourmehr, Sanam Dolati, Robab Mehdipour, Afra Memar, Farnaz Ghafourian, Avin Shakiba, Nasrin Abolhasanpour
Biomedical Research Bulletin, doi:10.34172/biomedrb.2023.06
Background: The coronavirus disease 2019 (COVID-19) exhibits the most important global public health emergency. Montelukast (MTL), a prototype cysteinyl leukotriene receptor antagonist, is commonly considered in the therapy of exercise-and aspirin-induced asthma. The purpose of this study was to present a systematic review of the literature on the effectiveness of MTL against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and exuberant immune activation in COVID-19 disease. Methods: PubMed, EMBASE, Web of Science, and Cochrane Central Register of Controlled Trials were searched from the database on August 15, 2021and updated on November 19, 2022. Two reviewers independently screened articles, appraised methodological quality, and extracted the data. Results: A total of 118 related reports were recognized after eliminating duplicates. Of these, 30 references were screened based on titles and abstracts. After removing unrelated studies, 20 studies were included in the full-text review and evaluated for appropriateness. Finally, eight studies fitting the inclusion criteria for data extraction were selected. One of them was a prospective, randomized, controlled, and single-blinded study, three were open-label randomized or non-randomized controlled clinical trials, two were retrospective studies, and two were case series or comparative studies. A total of 1083 patients infected with COVID-19 infection (999 adults and 84 children) were examined on the effectiveness of MTL on symptom severity as well as hospitalization length. The results of the mentioned studies showed a low risk of clinical deterioration in the MTL group. In addition, the length of hospital stay was low in the treatment group compared to the standard management. Conclusion: MTL as a potential adjuvant therapy in COVID-19 may improve lung injury, inflammation, and symptoms. Moreover, the use of MTL could decrease the severity and mortality of COVID-19. Additional well-designed randomized controlled trials are necessary to approve the role of MTL in SARS-CoV-2 prevention or COVID-19 symptoms improvement.
Competing Interests There is no conflict of interests.
Ethical Approval Not applicable.
Supplementary Files Supplementary file 1 depicts search strategy methods in PubMed and Cochrane databases.
References
Aigner, Pietrantonio, De Sousa, Michael, Schuster et al., The leukotriene receptor antagonist montelukast as a potential COVID-19 therapeutic, Front Mol Biosci,
doi:10.3389/fmolb.2020.610132Almerie, Kerrigan, The association between obesity and poor outcome after COVID-19 indicates a potential therapeutic role for montelukast, Med Hypotheses,
doi:10.1016/j.mehy.2020.109883Barré, Sabatier, Annweiler, Montelukast drug may improve COVID-19 prognosis: a review of evidence, Front Pharmacol,
doi:10.3389/fphar.2020.01344Bourgonje, Abdulle, Timens, Hillebrands, Navis et al., Angiotensin-converting enzyme 2 (ACE2), SARS-CoV-2 and the pathophysiology of coronavirus disease 2019 (COVID-19), J Pathol,
doi:10.1002/path.5471Cardani, Boulton, Kim, Braciale, Alveolar macrophages prevent lethal influenza pneumonia by inhibiting infection of type-1 alveolar epithelial cells, PLoS Pathog,
doi:10.1371/journal.ppat.1006140Chen, Li, Wang, Zou, Montelukast, an antiasthmatic drug, inhibits Zika virus infection by disrupting viral integrity, Front Microbiol,
doi:10.3389/fmicb.2019.03079Funk, Ardakani, A novel strategy to mitigate the hyperinflammatory response to COVID-19 by targeting leukotrienes, Front Pharmacol,
doi:10.3389/fphar.2020.01214Hm, Gareeb, Almulaiky, Cruz-Martins, Batiha, Role of leukotriene pathway and montelukast in pulmonary and extrapulmonary manifestations of COVID-19: the enigmatic entity, Eur J Pharmacol,
doi:10.1016/j.ejphar.2021.174196Hussein, Ibrahim, Makhlouf, Makhlouf, Abd-Elaal et al., Value of montelukast as a potential treatment of post-COVID-19 persistent cough: a non-randomized controlled pilot study, Egypt J Bronchol
Jiang, Deng, Zhang, Cai, Cheung et al., Review of the clinical characteristics of coronavirus disease 2019 (COVID-19), J Gen Intern Med,
doi:10.1007/s11606-020-05762-wKerget, Kerget, Aydın, Karaşahin, Effect of montelukast therapy on clinical course, pulmonary function, and mortality in patients with COVID-19, J Med Virol,
doi:10.1002/jmv.27552Lima-Morales, Méndez-Hernández, Flores, Osorno-Romero, Hernández et al., Effectiveness of a multidrug therapy consisting of Ivermectin, Azithromycin, Montelukast, and Acetylsalicylic acid to prevent hospitalization and death among ambulatory COVID-19 cases in Tlaxcala, Mexico, Int J Infect Dis,
doi:10.1016/j.ijid.2021.02.014Lin, Huang, Lee, Hsieh, Kuo et al., Effects of montelukast on M2-related cytokine and chemokine in M2 macrophages, J Microbiol Immunol Infect,
doi:10.1016/j.jmii.2016.04.005Mostafaei, Ghojazadeh, Hajebrahimi, Abolhasanpour, Salehi-Pourmehr, Clinical presentation of Iranian patients affected with COVID-19: a thousand faces disease, Iran J Allergy Asthma Immunol
Mostafaei, Hajebrahimi, Sadeghi-Ghyassi, Mostafaei, Abolhasanpour et al., Can wearing a face mask protect from COVID-19? A systematic review, Iran J Med Microbiol,
doi:10.30699/ijmm.14.2.101Norouzi, Treatment of SARS-CoV-2 (COVID-19) cases by the oral administration of montelukast tablets, Rev Bionatura,
doi:10.21931/rb/2020.05.04.5Page, Mckenzie, Bossuyt, Boutron, Hoffmann et al., The PRISMA 2020 statement: an updated guideline for reporting systematic reviews, Int J Surg,
doi:10.1016/j.ijsu.2021.105906Parisi, Manti, Papale, Giallongo, Indolfi et al., Addition of a nutraceutical to montelukast or inhaled steroid in the treatment of wheezing during COVID-19 pandemic: a multicenter, open-label, randomized controlled trial, Acta Biomed,
doi:10.23750/abm.v93i2.11958Shahsavarinia, Faridaalaee, Soleimanpour, Sadeghi-Ghyassi, Atashgahi et al., Cerebral venous thrombosis (CVT) Following COVID-19 vaccination: an umbrella review of systematic reviews, Iran J Med Microbiol
Soltani, Nasirharandi, Khorvash, Nasirian, Dolatshahi et al., The effectiveness of gabapentin and gabapentin/montelukast combination compared with dextromethorphan in the improvement of COVID-19-related cough: a randomized, controlled clinical trial, Clin Respir J,
doi:10.1111/crj.13529Tavares, Farraia, Silva, Ribeiro, Severo et al., Impact of montelukast as add on treatment to the novel coronavirus pneumonia (COVID-19): protocol for an investigator-initiated open labeled randomized controlled pragmatic trial, Porto Biomed J,
doi:10.1097/j.pbj.0000000000000134Wu, Hao, Lau, Wong, Leung et al., Real-time tentative assessment of the epidemiological characteristics of novel coronavirus infections in Wuhan, China, as at 22 January 2020, Euro Surveill,
doi:10.2807/1560-7917.es.2020.25.3.2000044Xu, Shi, Wang, Zhang, Huang et al., Pathological findings of COVID-19 associated with acute respiratory distress syndrome, Lancet Respir Med,
doi:10.1016/s2213-2600(20)30076-x{ 'indexed': {'date-parts': [[2023, 8, 9]], 'date-time': '2023-08-09T04:28:57Z', 'timestamp': 1691555337423},
'reference-count': 0,
'publisher': 'Maad Rayan Publishing Company',
'issue': '1',
'content-domain': {'domain': ['biomedrb.com'], 'crossmark-restriction': False},
'published-print': {'date-parts': [[2023, 3, 30]]},
'abstract': '<jats:p>Background: The coronavirus disease 2019 (COVID‐19) exhibits the most important '
'global public health emergency. Montelukast (MTL), a prototype cysteinyl leukotriene receptor '
'antagonist, is commonly considered in the therapy of exercise- and aspirin-induced asthma. '
'The purpose of this study was to present a systematic review of the literature on the '
'effectiveness of MTL against severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2) and '
'exuberant immune activation in COVID‐19 disease. Methods: PubMed, EMBASE, Web of Science, and '
'Cochrane Central Register of Controlled Trials were searched from the database on August 15, '
'2021and updated on November 19, 2022. Two reviewers independently screened articles, '
'appraised methodological quality, and extracted the data. Results: A total of 118 related '
'reports were recognized after eliminating duplicates. Of these, 30 references were screened '
'based on titles and abstracts. After removing unrelated studies, 20 studies were included in '
'the full-text review and evaluated for appropriateness. Finally, eight studies fitting the '
'inclusion criteria for data extraction were selected. One of them was a prospective, '
'randomized, controlled, and single-blinded study, three were open-label randomized or '
'non-randomized controlled clinical trials, two were retrospective studies, and two were case '
'series or comparative studies. A total of 1083 patients infected with COVID-19 infection (999 '
'adults and 84 children) were examined on the effectiveness of MTL on symptom severity as well '
'as hospitalization length. The results of the mentioned studies showed a low risk of clinical '
'deterioration in the MTL group. In addition, the length of hospital stay was low in the '
'treatment group compared to the standard management. Conclusion: MTL as a potential adjuvant '
'therapy in COVID-19 may improve lung injury, inflammation, and symptoms. Moreover, the use of '
'MTL could decrease the severity and mortality of COVID-19. Additional well-designed '
'randomized controlled trials are necessary to approve the role of MTL in SARS-CoV-2 '
'prevention or COVID-19 symptoms improvement. </jats:p>',
'DOI': '10.34172/biomedrb.2023.06',
'type': 'journal-article',
'created': {'date-parts': [[2023, 8, 8]], 'date-time': '2023-08-08T08:39:22Z', 'timestamp': 1691483962000},
'page': '19-29',
'update-policy': 'http://dx.doi.org/10.34172/crossmark_policy',
'source': 'Crossref',
'is-referenced-by-count': 0,
'title': 'Effect of Montelukast on Treatment of Coronavirus Pneumonia (COVID-19): A Systematic Review',
'prefix': '10.34172',
'volume': '1',
'author': [ { 'ORCID': 'http://orcid.org/0000-0001-9030-2106',
'authenticated-orcid': True,
'given': 'Hanieh',
'family': 'Salehi-Pourmehr',
'sequence': 'first',
'affiliation': [ { 'name': 'Research Center for Evidence-Based Medicine, Iranian EBM Centre: '
'A Joanna Briggs Institute (JBI) Center of Excellence, Tabriz '
'University of Medical Sciences, Tabriz, Iran'}]},
{ 'given': 'Sanam',
'family': 'Dolati',
'sequence': 'additional',
'affiliation': [ { 'name': 'Physical Medicine and Rehabilitation Research Center, Aging '
'Research Institute, Tabriz University of Medical Sciences, '
'Tabriz, Iran'}]},
{ 'given': 'Robab',
'family': 'Mehdipour',
'sequence': 'additional',
'affiliation': [ { 'name': 'Research Center for Evidence-Based Medicine, Iranian EBM Centre: '
'A Joanna Briggs Institute (JBI) Center of Excellence, Tabriz '
'University of Medical Sciences, Tabriz, Iran'}]},
{ 'given': 'Afra',
'family': 'Memar',
'sequence': 'additional',
'affiliation': [ { 'name': 'Student Research Committee, Tabriz University of Medical '
'Sciences, Tabriz, Iran'}]},
{ 'given': 'Farnaz',
'family': 'Ghafourian',
'sequence': 'additional',
'affiliation': [ { 'name': 'Student Research Committee, Tabriz University of Medical '
'Sciences, Tabriz, Iran'}]},
{ 'given': 'Avin',
'family': 'Shakiba',
'sequence': 'additional',
'affiliation': [ { 'name': 'Research Center for Evidence-Based Medicine, Iranian EBM Centre: '
'A Joanna Briggs Institute (JBI) Center of Excellence, Tabriz '
'University of Medical Sciences, Tabriz, Iran'}]},
{ 'ORCID': 'http://orcid.org/0000-0002-2606-5772',
'authenticated-orcid': True,
'given': 'Nasrin',
'family': 'Abolhasanpour',
'sequence': 'additional',
'affiliation': [ { 'name': 'Research Center for Evidence-Based Medicine, Iranian EBM Centre: '
'A Joanna Briggs Institute (JBI) Center of Excellence, Tabriz '
'University of Medical Sciences, Tabriz, Iran'}]}],
'member': '20123',
'published-online': {'date-parts': [[2023, 3, 30]]},
'container-title': 'Biomedical Research Bulletin',
'original-title': [],
'language': 'en',
'link': [ { 'URL': 'http://biomedrb.com/PDF/brb-9.pdf',
'content-type': 'application/pdf',
'content-version': 'vor',
'intended-application': 'text-mining'},
{ 'URL': 'http://biomedrb.com/PDF/brb-9.pdf',
'content-type': 'unspecified',
'content-version': 'vor',
'intended-application': 'similarity-checking'}],
'deposited': { 'date-parts': [[2023, 8, 8]],
'date-time': '2023-08-08T08:39:22Z',
'timestamp': 1691483962000},
'score': 1,
'resource': {'primary': {'URL': 'http://biomedrb.com/Article/brb-9'}},
'subtitle': [],
'short-title': [],
'issued': {'date-parts': [[2023, 3, 30]]},
'references-count': 0,
'journal-issue': {'issue': '1', 'published-print': {'date-parts': [[2023, 3, 30]]}},
'URL': 'http://dx.doi.org/10.34172/biomedrb.2023.06',
'relation': {},
'ISSN': ['2980-9924'],
'container-title-short': 'Biomed Res Bull',
'published': {'date-parts': [[2023, 3, 30]]},
'assertion': [ { 'value': '2022-12-22',
'order': 1,
'name': 'received',
'label': 'Received',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2023-01-22',
'order': 2,
'name': 'accepted',
'label': 'Accepted',
'group': {'name': 'publication_history', 'label': 'Publication History'}},
{ 'value': '2023-03-30',
'order': 3,
'name': 'published',
'label': 'Published',
'group': {'name': 'publication_history', 'label': 'Publication History'}}]}
